{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:02:14Z","timestamp":1792029734686,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche Pharma AG, Germany"},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ocrelizumab is a B cell-depleting drug widely used in relapsing\u2013remitting multiple sclerosis (RRMS) and primary-progressive MS. In RRMS, it is becoming increasingly apparent that accumulation of disability not only manifests as relapse-associated worsening (RAW) but also as progression independent of relapse activity (PIRA) throughout the disease course. This study\u2019s objective was to investigate the role of PIRA in RRMS patients treated with ocrelizumab. We performed a single-center, retrospective, cross-sectional study of clinical data acquired at a German tertiary multiple sclerosis referral center from 2018 to 2022. All patients with RRMS treated with ocrelizumab for at least six months and complete datasets were analyzed. Confirmed disability accumulation (CDA) was defined as a\u2009\u2265\u200912-week confirmed increase from the previous expanded disability status scale (EDSS) score of\u2009\u2265\u20091.0 if the previous EDSS was\u2009\u2264\u2009 5.5 or a\u2009\u2265\u20090.5-point increase if the previous EDSS was\u2009&gt;\u20095.5. PIRA was defined as CDA without relapse since the last EDSS measurement and at least for the preceding 12 weeks. RAW was defined as CDA in an interval of EDSS measurements with\u2009\u2265\u20091 relapses. Cox proportional hazard models were used to analyze the probability of developing PIRA depending on various factors, including disease duration, previous disease-modifying treatments (DMTs), and optical coherence tomography-assessed retinal degeneration parameters. 97 patients were included in the analysis. Mean follow-up time was 29 months (range 6 to 51 months). 23.5% developed CDA under ocrelizumab therapy (n\u2009=\u200923). Of those, the majority developed PIRA (87.0% of CDA, n\u2009=\u200920) rather than RAW (13.0% of CDA, n\u2009=\u20093). An exploratory investigation using Cox proportional hazards ratios revealed two possible factors associated with an increased probability of developing PIRA: a shorter disease duration prior to ocrelizumab (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and a lower number of previous DMTs prior to ocrelizumab (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). Our data show that in ocrelizumab-treated RRMS patients, the main driver of disability accumulation is PIRA rather than RAW. Furthermore, these real-world data show remarkable consistency with data from phase 3 randomized controlled trials of ocrelizumab in RRMS, which may increase confidence in translating results from tightly controlled RCTs into the real-world clinical setting.<\/jats:p>","DOI":"10.1038\/s41598-023-40940-w","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T16:02:17Z","timestamp":1694448137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials"],"prefix":"10.1038","volume":"13","author":[{"given":"J.","family":"Ingwersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Masanneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"40940_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann. Neurol. 85, 653\u2013666 (2019).","journal-title":"Ann. Neurol."},{"key":"40940_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40263-022-00977-3","volume":"37","author":"NG Dimitriou","year":"2023","unstructured":"Dimitriou, N. G., Meuth, S. G., Martinez-Lapiscina, E. H., Albrecht, P. & Menge, T. Treatment of patients with multiple sclerosis transitioning between relapsing and progressive disease. CNS Drugs 37, 69\u201392 (2023).","journal-title":"CNS Drugs"},{"key":"40940_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1352458517709619","volume":"24","author":"L Kappos","year":"2018","unstructured":"Kappos, L. et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Scler. 24, 963\u2013973 (2018).","journal-title":"Multiple Scler."},{"key":"40940_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L. et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 77, 1132\u20131140 (2020).","journal-title":"JAMA Neurol."},{"key":"40940_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"BAC Cree","year":"2016","unstructured":"Cree, B. A. C. et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann. Neurol. 80, 499\u2013510 (2016).","journal-title":"Ann. Neurol."},{"key":"40940_CR6","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin, F. D. et al. How patients with multiple sclerosis acquire disability. Brain 145, 3147\u20133161 (2022).","journal-title":"Brain"},{"key":"40940_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"40940_CR8","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman, R. E. et al. Real-world evidence\u2014What is it and what can it tell us?. N. Engl. J. Med. 375, 2293\u20132297 (2016).","journal-title":"N. Engl. J. Med."},{"key":"40940_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1212\/NXI.0000000000001035","volume":"8","author":"L Rolfes","year":"2021","unstructured":"Rolfes, L. et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol. (R) Neuroimmunol. Neuroinflam. 8, 1035 (2021).","journal-title":"Neurol. (R) Neuroimmunol. Neuroinflam."},{"key":"40940_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/jnnp-2021-328197","volume":"93","author":"S R\u00e4uber","year":"2022","unstructured":"R\u00e4uber, S. et al. Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. J. Neurol. Neurosurg. Psychiatry 93, 978\u2013985 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"40940_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51732","author":"X Montalban","year":"2023","unstructured":"Montalban, X. et al. Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. Annals Clin. Transl. Neurol https:\/\/doi.org\/10.1002\/acn3.51732 (2023).","journal-title":"Annals Clin. Transl. Neurol"},{"key":"40940_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"40940_CR13","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"86","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz, A. et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 86, 2303\u20132309 (2016).","journal-title":"Neurology"},{"key":"40940_CR14","doi-asserted-by":"publisher","first-page":"e49825","DOI":"10.1371\/journal.pone.0049825","volume":"7","author":"P Albrecht","year":"2012","unstructured":"Albrecht, P. et al. Retinal neurodegeneration in Wilson\u2019s disease revealed by spectral domain optical coherence tomography. PLoS ONE 7, e49825 (2012).","journal-title":"PLoS ONE"},{"key":"40940_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/acn3.46","volume":"1","author":"M Ringelstein","year":"2014","unstructured":"Ringelstein, M. et al. Subtle retinal pathology in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 1, 290\u2013297 (2014).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"40940_CR16","doi-asserted-by":"publisher","first-page":"e1099","DOI":"10.1212\/NXI.0000000000001099","volume":"9","author":"J Ingwersen","year":"2022","unstructured":"Ingwersen, J. et al. CNS involvement in chronic inflammatory demyelinating polyneuropathy: Subtle retinal changes in optical coherence tomography. Neurol.(R) Neuroimmunol. Neuroinflamm. 9, e1099 (2022).","journal-title":"Neurol.(R) Neuroimmunol. Neuroinflamm."},{"key":"40940_CR17","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie, P. et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE 7, e34823 (2012).","journal-title":"PLoS ONE"},{"key":"40940_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"40940_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","volume":"585","author":"CR Harris","year":"2020","unstructured":"Harris, C. R. et al. Array programming with NumPy. Nature 585, 357\u2013362 (2020).","journal-title":"Nature"},{"key":"40940_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: A 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"40940_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21105\/joss.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon, C. Lifelines: Survival analysis in Python. JOSS 4, 1317 (2019).","journal-title":"JOSS"},{"key":"40940_CR22","first-page":"1354","volume":"2022","author":"A Kline","year":"2022","unstructured":"Kline, A. & Luo, Y. PsmPy: A package for retrospective cohort matching in python. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2022, 1354\u20131357 (2022).","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"key":"40940_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/braincomms\/fcab229","volume":"3","author":"J Graf","year":"2021","unstructured":"Graf, J. et al. Relapse-independent multiple sclerosis progression under natalizumab. Brain Commun. 3, 229 (2021).","journal-title":"Brain Commun."},{"key":"40940_CR24","doi-asserted-by":"publisher","first-page":"103927","DOI":"10.1016\/j.msard.2022.103927","volume":"63","author":"L Masanneck","year":"2022","unstructured":"Masanneck, L. et al. Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies. Multiple Scler. Relat. Disord. 63, 103927 (2022).","journal-title":"Multiple Scler. Relat. Disord."},{"key":"40940_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1352458519892555","volume":"26","author":"JA Cohen","year":"2020","unstructured":"Cohen, J. A. et al. Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Multiple Scler. 26, 23\u201337 (2020).","journal-title":"Multiple Scler."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40940-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T19:12:46Z","timestamp":1700593966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40940-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40940"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-40940-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JI reports no conflicts of interest and funding by the Bundesinstitut f\u00fcr Risikobewertung (BfR), LM received honoraria from Biogen and Merck, as well as research funding from the Deutsche Multiple Sklerose Gesellschaft, MP received honoraria for lecturing from Argenx, Alexion, Novartis, Bayer Health Care, Sanofi-Aventis, Biogen and Merck; SS received no financial compensation or support from any organization or entity that may have an interest in the content of this manuscript; MW declares nor conflict of interest and nor funding received for the preparation of this report; OA has received, with approval of the Heinrich Heine University, advisor fees, honoraria, or travel reimbursements from Alexion, Almirall, Biogen, Horizon, MedImmune, Merck, Novartis, Roche, and Teva; research support from the German Science Foundation (DFG), the German Ministry of Education and Research (BMBF), Biogen, and Novartis. He is member of the European Reference Network\u2014Eye Diseases (ERN-EYE) consortium and member of the German Neuromyelitis optica Study Group (NEMOS); SGM received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut f\u00fcr Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva; PA received research grants from BMS, Celgene, German Research Association, EFRE NRW, Ipsen, Merck, Merz, Novartis and speaker honoraria, travel support and recompensation for serving on advisory boards from Allergan, Abbvie, BMS, Celgene, Ipsen, Hexal, Janssen Cilag, Lilly, Merck, Merz, Novartis, Sanofi, TEVA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15003"}}